Gwendolyn A. McMillin, BA, PhD, MA

Languages

  • English

Academic Information

  • Departments: Pathology - Professor (Clinical)
  • Divisions: Clinical Pathology

Board Certification

  • American Board of Clinical Chemistry (Sub: Clinical Chemistry)
  • American Board of Clinical Chemistry (Sub: Toxicological Chemistry)

Academic Office Information

  • 801-583-2787
  • ARUP
    500 Chipeta Way
    Salt Lake City, UT 84108

Email: gwen.mcmillin@aruplab.com

Academic Bio

Dr. McMillin received her PhD in pharmacology and toxicology from the University of Utah.

Dr. McMillin is a Medical Director of the Toxicology and Trace Elements laboratories and Co-Medical Director of Pharmacogenetics at ARUP, as well as a Professor of Pathology at the University of Utah School of Medicine. Dr. McMillin is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry.

Education History

Type School Degree
Postdoctoral Fellowship University of Utah School of Medicine
Clinical Chemistry and Laboratory Medicine
Postdoctoral Fellow
Doctoral Training University of Utah
Pharmacology and Toxicology
Ph.D.
Undergraduate Grinnell College
Psychology
B.A.

Selected Publications

Journal Article

  1. Wu F, Jensen TL, McMillin GA (2019). Detection of In Utero Cannabis Exposure in Umbilical Cord Tissue by a Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method. Methods Mol Biol, 1872, 211-222.
  2. Metz TD, Silver RM, McMillin GA, Allshouse AA, Jensen TL, Mansfield C, Heard K, Kinney GL, Wymore E, Binswanger IA (2019 Jan). Prenatal Marijuana Use by Self-Report and Umbilical Cord Sampling in a State With Marijuana Legalization. Obstet Gynecol, 133(1), 98-104.
  3. Wabuyele SL, McMillin GA (2019). Quantitation of Ethyl-beta-D-Glucuronide in Human Umbilical Cord Tissue by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). Methods Mol Biol, 1872, 223-236.
  4. Wabuyele SL, Colby JM, McMillin GA (2018 Apr). Detection of Drug-Exposed Newborns. Ther Drug Monit, 40(2), 166-185.
  5. Scroggin TL, McMillin GA (2018 Apr 1). Quantitation of Cocaine and Metabolites, Phencyclidine, Butalbital and Phenobarbital in Meconium by Liquid Chromatography-Tandem Mass Spectrometry. J Anal Toxicol, 42(3), 177-182.
  6. McMillin GA (). Pharmacogenetics of opioid use and implications for pain management – are we ready? J Appl Lab Med, 2(4), 481-4.
  7. Wu F, Scroggin TL, Metz TD, McMillin GA (2018 Jan 1). Development of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Four Cannabinoids in Umbilical Cord Tissue. J Anal Toxicol, 42(1), 42-48.
  8. Jannetto PJ, Bratanow NC, Clark WA, Hamill-Ruth RJ, Hammett-Stabler CA, Huestis MA, Kassed CA, McMillin GA, Melanson SE, Langman LJ (). Executive summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline – using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med, 2(4), 489-526.
  9. McMillin GA (). Drug detection in urine for evaluating exposure. J Appl Lab Med, 2(4), 648-53.
  10. Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodriguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple BD, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Davila-Roman V, Eby CS (2017 Sep 26). Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. JAMA, 318(12), 1115-1124.
  11. Wu F, Marin SJ, McMillin GA (2017 Apr 1). Stability of 21 Cocaine, Opioid and Benzodiazepine Drug Analytes in Spiked Meconium at Three Temperatures. J Anal Toxicol, 41(3), 196-204.
  12. Wu F, Marin SJ, Clark CJ, McMillin GA (2017). Stability of 21 Cocaine, Opioid, and Benzodiazepine Drug Analytes in Meconium at 3 Temperatures. Am J Clin Pathol, 147(suppl_2), S14.
  13. Leung EY, Agolini E, Pei X, Melis R, McMillin GA, Friedman PN, Peterson P, Danahey K, ODonnell PH, Yeo KJ (). Validation of an Extensive CYP2D6 Assay Panel Based on Invader and TaqMan Copy Number Assays. J Appl Lab Med, 1(5), 471-82.
  14. Powers JL, Buys SS, Fletcher D, Melis R, Johnson-Davis KL, Lyon E, Malmberg EM, McMillin GA (2016 Dec). Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. J Clin Pharmacol, 56(12), 1570-1581.
  15. Hyun G, Li J, Bass AR, Mohapatra A, Woller SC, Lin H, Eby C, McMillin GA, Gage BF (2016 Nov). Use of signals and systems engineering to improve the safety of warfarin initiation. J Thromb Thrombolysis, 42(4), 529-33.
  16. Haglock-Adler CJ, McMillin GA, Strathmann FG (2016 Sep). Development of a liquid chromatography-tandem mass spectrometry method to address the increased utilization of umbilical cord in the assessment of in utero drug exposure. Clin Biochem, 49(13-14), 1092-5.
  17. Kalman LV, Agundez J, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Caudle K, Coulthard SA, Daly AK, Del Tredici A, den Dunnen JT, Drozda K, Everts RE, Flockhart D, Freimuth RR, Gaedigk A, Hachad H, Hartshorne T, Ingelman-Sundberg M, Klein TE, Lauschke VM, Maglott DR, McLeod HL, McMillin GA, Meyer UA, Muller DJ, Nickerson DA, Oetting WS, Pacanowski M, Pratt VM, Relling MV, Roberts A, Rubinstein WS, Sangkuhl K, Schwab M, Scott SA, Sim SC, Thirumaran RK, Toji LH, Tyndale RF, van Schaik R, Whirl-Carrillo M, Yeo K, Zanger UM (2016 Feb). Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharmacol Ther, 99(2), 172-85.
  18. Marin SJ, McMillin GA (2016). Quantitation of Total Buprenorphine and Norbuprenorphine in Meconium by LC-MS/MS. Methods Mol Biol, 1383, 59-68.
  19. Marin SJ, McMillin GA (2016). Quantitation of Buprenorphine, Norbuprenorphine, Buprenorphine Glucuronide, Norbuprenorphine Glucuronide, and Naloxone in Urine by LC-MS/MS. Methods Mol Biol, 1383, 69-78.
  20. McMillin GA, Wood KE, Strathmann FG, Krasowski MD (2015 Oct). Patterns of Drugs and Drug Metabolites Observed in Meconium: What Do They Mean? Ther Drug Monit, 37(5), 568-80.
  21. McMillin GA, Marin SJ, Johnson-Davis KL, Lawlor BG, Strathmann FG (2015 Feb). A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. Am J Clin Pathol, 143(2), 234-40.
  22. Suh-Lailam BB, Haglock-Adler CJ, Carlisle HJ, Ohman T, McMillin GA (2014 Sep). Reference interval determination for anabasine: a biomarker of active tobacco use. J Anal Toxicol, 38(7), 416-20.
  23. Wood KE, Krasowski MD, Strathmann FG, McMillin GA (2014 Sep). Meconium drug testing in multiple births in the USA. J Anal Toxicol, 38(7), 397-403.
  24. Wood KE, Sinclair LL, Rysgaard CD, Strathmann FG, McMillin GA, Krasowski MD (2014 Jul 29). Retrospective analysis of the diagnostic yield of newborn drug testing. BMC Pregnancy and Childbirth, 14, 250.
  25. Marin SJ, Metcalf A, Krasowski MD, Linert BS, Clark CJ, Strathmann FG, McMillin GA (2014 Feb). Detection of neonatal drug exposure using umbilical cord tissue and liquid chromatography time-of-flight mass spectrometry. Ther Drug Monit, 36(1), 119-24.
  26. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH (2013 Dec 12). A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med, 369(24), 2283-93.
  27. Chittamma A, Marin SJ, Williams JA, Clark C, McMillin GA (2013 Sep). Detection of in utero marijuana exposure by GC-MS, ultra-sensitive ELISA and LC-TOF-MS using umbilical cord tissue. J Anal Toxicol, 37(7), 391-4.
  28. Lin CN, Nelson GJ, McMillin GA (2013 Jan-Feb). Evaluation of the NexScreen and DrugCheck Waive RT urine drug detection cups. J Anal Toxicol, 37(1), 30-6.
  29. Do EJ, Lenzini P, Eby CS, Bass AR, McMillin GA, Stevens SM, Woller SC, Pendleton RC, Anderson JL, Proctor P, Nunley RM, Davila-Roman V, Gage BF (). Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics, 12(5), 417-24.
  30. Marin SJ, Roberts M, Wood M, McMillin GA (2012 Sep). Sensitive UPLC-MS-MS assay for 21 benzodiazepine drugs and metabolites, zolpidem and zopiclone in serum or plasma. J Anal Toxicol, 36(7), 472-6.
  31. Borgman MP, Pendleton RC, McMillin GA, Reynolds KK, Vazquez S, Freeman A, Wilson A, Valdes R Jr, Linder MW (2012 Sep). Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. Thromb Haemost, 108(3), 561-9.
  32. Barakauskas VE, Davis R, Krasowski MD, McMillin GA (2012). Unresolved discrepancies between cannabinoid test results for infant urine. Clin Chem, 58(9), 1364-7.
  33. Marin SJ, Hughes JM, Lawlor BG, Clark CJ, McMillin GA (2012). Rapid screening for 67 drugs and metabolites in serum or plasma by accurate-mass LC-TOF-MS. J Anal Toxicol, 36(7), 477-86.
  34. Melis R, Lewis T, Millson A, Lyon E, McMillin GA, Slev PR, Swensen J (2012 Sep). Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity. Genet Test Mol Biomarkers, 16(9), 1111-4.
  35. Johnson-Davis KL, Thompson CD, Clark CJ, McMillin GA, Lehman CM (2012 Jun). Method comparison of the Ortho Vitros Fusion 5,1 chemistry analyzer and the Roche COBAS Integra 400 for urine drug screen testing in the emergency department. J Anal Toxicol, 36(5), 345-8.
  36. McMillin GA, Johnson-Davis K, Dasgupta A (2012 Apr). Analytical performance of a new liquid chromatography/tandem mass spectrometric method for determination of everolimus concentrations in whole blood. Ther Drug Monit, 34(2), 222-6.
  37. Lin CN, Wilson A, Church BB, Ehman S, Roberts WL, McMillin GA (2012 Mar 22). Pediatric reference intervals for serum copper and zinc. Clin Chim Acta, 413(5-6), 612-5.
  38. McMillin GA, Davis R, Carlisle H, Clark C, Marin SJ, Moody DE (2012 Mar). Patterns of free (unconjugated) buprenorphine, norbuprenorphine, and their glucuronides in urine using liquid chromatography-tandem mass spectrometry. J Anal Toxicol, 36(2), 81-7.
  39. Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage BF (2012 Feb). Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost, 107(2), 232-40.
  40. Johnson-Davis KL, Juenke JM, Davis R, McMillin GA (2012). Quantification of tricyclic antidepressants using UPLC-MS/MS. Methods Mol Biol, 902, 175-84.
  41. Raval G, Straughen JE, McMillin GA, Bornhorst JA (2011 Nov). Unexplained hemolytic anemia with multiorgan failure. Clin Chem, 57(11), 1485-8.
  42. Juenke JM, Miller KA, Ford MA, McMillin GA, Johnson-Davis KL (2011 Sep 18). A comparison of two FDA approved lamotrigine immunoassays with ultra-high performance liquid chromatography tandem mass spectrometry. Clin Chim Acta, 412(19-20), 1879-82.
  43. Johnson-Davis KL, De S, Jimenez E, McMillin GA, De BK (2011 Aug). Evaluation of the Abbott ARCHITECT i2000 sirolimus assay and comparison with the Abbott IMx sirolimus assay and an established liquid chromatography-tandem mass spectrometry method. Ther Drug Monit, 33(4), 453-9.
  44. Juenke JM, Hardy L, McMillin GA, Horowitz GL (2011 Aug). Rapid and specific quantification of ethylene glycol levels: adaptation of a commercial enzymatic assay to automated chemistry analyzers. Am J Clin Pathol, 136(2), 318-24.
  45. Juenke JM, Wienhoff KA, Anderson BL, McMillin GA, Johnson-Davis KL (2011 Aug). Performance characteristics of the ARK diagnostics gabapentin immunoassay. Ther Drug Monit, 33(4), 398-401.
  46. Melis R, Fauron C, McMillin G, Lyon E, Shirts B, Hubley LM, Slev PR (). Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn, 13(4), 446-51.
  47. Juenke JM, Miller KA, McMillin GA, Johnson-Davis KL (2011 Jun). An automated method for supporting busulfan therapeutic drug monitoring. Ther Drug Monit, 33(3), 315-20.
  48. McMillin GA, Juenke JM, Johnson MJ, Dasgupta A (). Discordant carbamazepine values between two immunoassays: carbamazepine values determined by ADVIA Centaur correlate better with those determined by LC-MS/MS than PETINIA assay. J Clin Lab Anal, 25(3), 212-6.
  49. Marin SJ, Christensen RD, Baer VL, Clark CJ, McMillin GA (2011 Feb). Nicotine and metabolites in paired umbilical cord tissue and meconium specimens. Ther Drug Monit, 33(1), 80-5.
  50. Juenke JM, Brown PI, Johnson-Davis KL, McMillin GA (). Simultaneous Quantification of Levetiracetam and Gabapentin in Plasma by Ultra-Pressure Liquid Chromatography Coupled with Tandem Mass Spectrometry Detection. Ther Drug Monit, 33(2), 209-13.
  51. Marin SJ, Merrell M, McMillin GA (2011 Jan). Drugs of abuse detection in meconium: a comparison between ELISA and biochip microarray. J Anal Toxicol, 35(1), 40-5.
  52. Greene DN, Lehman CM, McMillin GA (2011 Jan). Evaluation of the integrated E-Z split key((R)) cup II for rapid detection of twelve drug classes in urine. J Anal Toxicol, 35(1), 46-53.
  53. McMillin GA, Johnson-Davis KL (). Therapeutic drug monitoring of busulfan. Clin Chem, 57(4), 644-45.
  54. Lee C, McMillin GA, Babic N, Melis R, Yeo KTJ (). Evaluation of a CYP2C19 genotype panel on the GenMark eSensor ® platform and the comparison to the Autogenomics INFINITI™ and Luminex CYP2C19 panels. Clin Chim Acta, 412(11-12), 1133-37.
  55. Johnson-Davis KL, Thompson CD, Clark CJ, McMillin GA, Lehman CM (2010 Nov). High amphetamine/methamphetamine concentrations in urine can cause error codes on the Ortho Vitros(R) Fusion 5,1 FS automated chemistry analyzer. J Anal Toxicol, 34(9), 607-8.
  56. Johnson-Davis KL, McMillin GA, Juenke JM, Ford CD, Petersen FB (2010 Jul). Which dose of busulfan is best? Clin Chem, 56(7), 1061-4.
  57. Breaud AR, Harlan R, Di Bussolo JM, McMillin GA, Clarke W (2010 Jun 3). A rapid and fully-automated method for the quantitation of tricyclic antidepressants in serum using turbulent-flow liquid chromatography-tandem mass spectrometry. Clin Chim Acta, 411(11-12), 825-32.
  58. McMillin GA, Melis R, Wilson A, Strong MB, Wanner NA, Vinik RG, Peters CL, Pendleton RC (2010 Jun). Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Ther Drug Monit, 32(3), 338-45.
  59. McMillin GA, Juenke JM, Tso G, Dasgupta A (2010 May). Estimation of carbamazepine and carbamazepine-10,11-epoxide concentrations in plasma using mathematical equations generated with two carbamazepine immunoassays. Am J Clin Pathol, 133(5), 728-36.
  60. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF (2010 May). Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther, 87(5), 572-8.
  61. MacKay M, Winther B, Rusho B, McMillin GA, Jackson D (2009). The physical and chemical stability of iron sucrose in parenteral nutrition. Nutr Clin Pract, 24, 733-7.
  62. Marin SJ, McMillin GA (). LC-MS/MS analysis of 13 benzodiazepines and metabolites in urine, serum, plasma, and meconium. Methods Mol Biol.
  63. MacKay M, Rusho W, Jackson D, McMillin G, Winther B (2009 Dec). Physical and chemical stability of iron sucrose in parenteral nutrition. Nutr Clin Pract, 24(6), 733-7.
  64. De BK, Jimenez E, De S, Sawyer JC, McMillin GA (2009 Dec). Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx methods. Clin Chim Acta, 410(1-2), 25-30.
  65. Courtney JB, Harney R, Li Y, Lundell G, McMillin GA, Agarwal G, Juenke JM, Mathew A, Gonzalez-Espinoza R, Fleisher M, Salamone SJ (2009 Aug). Determination of busulfan in human plasma using an ELISA format. Ther Drug Monit, 31(4), 489-94.
  66. Marin SJ, Keith L, Merrell M, McMillin GA (2009 Apr). Evaluation of a new ELISA kit for the detection of benzodiazepines in meconium. J Anal Toxicol, 33(3), 177-81.
  67. Marin SJ, Keith L, Merrell M, McMillin GA (2009 Apr). Comparison of drugs of abuse detection in meconium by EMIT II and ELISA. J Anal Toxicol, 33(3), 148-54.
  68. Marin SJ, Moore C, McMillin GA (2009 Mar). Cross-reactivity of phentermine with an immunoassay designed to detect amphetamine in a meconium specimen. Clin Chem, 55(3), 589-90.
  69. McMillin GA, Travis JJ, Hunt JW (2009 Feb). Direct measurement of free copper in serum or plasma ultrafiltrate. Am J Clin Pathol, 131(2), 160-5.
  70. Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E, Harney RL, Hammett-Stabler C, Lepp S, Li Y, Lundell GD, McMillin G, Milano G, Salamone SJ (2009). Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit, 31(6), 688-94.
  71. Marin SJ, Coles R, Merrell M, McMillin GA (2008 Sep). Quantitation of benzodiazepines in urine, serum, plasma, and meconium by LC-MS-MS. J Anal Toxicol, 32(7), 491-8.
  72. Marin SJ, Coles R, Urry FM, McMillin GA (2007 Oct 15). Confirmation of cannabinoids in meconium using two-dimensional gas chromatography with mass spectrometry detection. J Chromatogr B Analyt Technol Biomed Life Sci, 858(1-2), 59-64.
  73. Yang X, Janatova J, Juenke JM, McMillin GA, Andrade JD (2007 Jun 15). An ImmunoChip prototype for simultaneous detection of antiepileptic drugs using an enhanced one-step homogeneous immunoassay. Anal Biochem, 365(2), 222-9.
  74. Coles R, Kushnir MM, Nelson GJ, McMillin GA, Urry FM (2007 Jan-Feb). Simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, oxycodone, and 6-acetylmorphine in urine, serum, plasma, whole blood, and meconium by LC-MS-MS. J Anal Toxicol, 31(1), 1-14.
  75. Juenke J, Brown PI, Urry FM, McMillin GA (2006 Jan-Feb). Drug monitoring and toxicology: a procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV. J Anal Toxicol, 30(1), 27-30.
  76. Juenke J, Brown P, Urry FM, McMillin GA (2006). Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV. J Chromatogr, 44(1), 45-8.
  77. McMillin GA, Juenke J, Dasgupta A (2005 Oct). Effect of ultrafiltrate volume on determination of free phenytoin concentration. Ther Drug Monit, 27(5), 630-3.
  78. Coles R, Clements TT, Nelson GJ, McMillin GA, Urry FM (2005 Sep). Simultaneous analysis of the Delta9-THC metabolites 11-nor-9-carboxy-Delta9-THC and 11-hydroxy-Delta9-THC in meconium by GC-MS. J Anal Toxicol, 29(6), 522-7.
  79. Bornhorst JA, Hunt JW, Urry FM, McMillin GA (2005 Apr). Comparison of sample preservation methods for clinical trace element analysis by inductively coupled plasma mass spectrometry. Am J Clin Pathol, 123(4), 578-83.
  80. Juenke JM, Brown PI, Urry FM, McMillin GA (2004 Aug). Specimen dilution for C2 monitoring with the Abbott TDxFLx cyclosporine monoclonal whole blood assay. Clin Chem, 50(8), 1430-3.
  81. Pickering JW, McMillin GA, Gedge F, Hill HR, Lyon E (2004). Flow cytometric assay for genotyping cytochrome p450 2C9 and 2C19: comparison with a microelectronic DNA array. Am J Pharmacogenomics, 4(3), 199-207.
  82. Juenke JM, Brown PI, McMillin GA, Urry FM (2004 Jan-Feb). A rapid procedure for the monitoring of amiodarone and N-desethylamiodarone by HPLC-UV detection. J Anal Toxicol, 28(1), 63-6.
  83. Juenke JM, Brown PI, McMillin GA, Urry FM (2003 Jul). Procedure for the monitoring of gabapentin with 2,4,6-trinitrobenzene sulfonic acid derivatization followed by HPLC with ultraviolet detection. Clin Chem, 49(7), 1198-201.
  84. McMillin GA, Owen WE, Lambert TL, De BK, Frank EL, Bach PR, Annesley TM, Roberts WL (2002 Sep). Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays. Clin Chem, 48(9), 1580-4.
  85. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH (2000). Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia, 41 Suppl 1, S17-20.
  86. Salvati P, Maj R, Caccia C, Cervini MA, Fornaretto MG, Lamberti E, Pevarello P, Skeen GA, White HS, Wolf HH, Faravelli L, Mazzanti M, Mancinelli E, Varasi M, Fariello RG (1999 Mar). Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther, 288(3), 1151-9.
  87. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH (1997 Oct). Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res, 28(3), 167-79.
  88. Filloux FM, Fitts RC, Skeen GA, White HS (1994 Nov 15). The dihydropyridine nitrendipine inhibits [3H]MK 801 binding to mouse brain sections. Eur J Pharmacol, 269(3), 325-30.
  89. Skeen GA, White HS, Twyman RE (1994 Oct). The dihydropyridine nitrendipine reduces N-methyl-D-aspartate (NMDA)-evoked currents of rodent cortical neurons through a direct interaction with the NMDA receptor-associated ion channel. J Pharmacol Exp Ther, 271(1), 30-8.
  90. Skeen GA, Twyman RE, White HS (1993 Aug). The dihydropyridine nitrendipine modulates N-methyl-D-aspartate receptor channel function in mammalian neurons. Mol Pharmacol, 44(2), 443-50.
  91. Swinyard EA, Wolf HH, White HS, Skeen GA, Stark LG, Albertson T, Pong SF, Drust EG (1993 May). Characterization of the anticonvulsant properties of F-721. Epilepsy Res, 15(1), 35-45.
  92. White HS, Wolf HH, Swinyard EA, Skeen GA, Sofia RD (1992 May-Jun). A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia, 33(3), 564-72.
  93. White HS, Skeen GA, Edwards JA (). Pharmacological regulation of astrocytic calcium channels: implications for the treatment of seizure disorders. Prog Brain Res, 94, 77-87.

Review

  1. Ji Y, Si Y, McMillin GA, Lyon E (2018 May). Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine. [Review]. Expert Rev Mol Diagn, 18(5), 411-421.
  2. Wabuyele SL, Colby JM, McMillin GA (). Detection of Drug-Exposed Newborns. [Review]. Ther Drug Monit Feb 5. [Review]. Ther Drug Monit, 40(2), 166-185.
  3. Krasowski MD, McMillin GA (2014 Sep 25). Advances in anti-epileptic drug testing. [Review]. Clin Chim Acta, 436, 224-36.
  4. McMillin GA, Slawson MH, Marin SJ, Johnson-Davis KL (2013 Dec). Demystifying analytical approaches for urine drug testing to evaluate medication adherence in chronic pain management. [Review]. J Pain Palliat Care Pharmacother, 27(4), 322-39.
  5. McMillin GA, Vazquez SR, Pendleton RC (2011 May). Current challenges in personalizing warfarin therapy. [Review]. Expert Rev Clin Pharmacol, 4(3), 349-62.
  6. Keil DE, Berger-Ritchie J, McMillin GA (). Testing for toxic elements; a focus on arsenic, cadmium, lead and mercury. [Review]. Lab Med, 42(12), 1-8.
  7. Lyon E, McMillin G, Melis R (2008). Pharmacogenetic testing for warfarin sensitivity. [Review]. Clin Lab Med, 28(4), 525-37.
  8. Melis R, Lyon E, McMillin GA (2006). Determination of CYP2D6, CYP2C9, and CYP2C19 genotypes with Tag-It mutation detection assays. [Review]. Expert Rev Mol Diagn, 6(6), 811-20.
  9. Bornhorst J, McMillin G (2006). Trace and toxic elemental testing in the clinical laboratory. [Review]. Lab Med, 37(11), 690-5.
  10. Clarke W, McMillin GA (May 2006). Application of TDM, pharmacogenomics and biomarkers for neuological disease pharmacotherapy: focus on antiepileptic drugs. [Review]. Per Med, 3(2), 139-49.
  11. McMillin G, Lyon E (). Contributions of genetic testing in personalized pharmacotherapy. Invited review for Advance News Magazine for Administrators of the Laboratory. [Review]. Adv Adm Lab, 15(4), 20.
  12. Clarke W, McMillin GA (April 2006). Emerging strategies for therapeutic drug management. [Review]. Clinical Laboratory News, 32(4), 10-2.

Book Chapter

  1. McMillin GA, Wadelius M, Pratt VM (). Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics. In Rifai N, Horvath AR, Wittwer CT (Eds.) (8th, chapter 46). St. Louis, MO: Elsevier Inc.
  2. McMillin GA, Wadelius M, Pratt VM (). Pharmacogenetics. In (Eds.), In (6th Ed., Chapter 54 – electronic only). St. Louis, MO: Elsevier Inc. In Rifai N, Horvath AR, Wittwer CT (Eds.), Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (6th, Chapter 54 (Electronic Only)). St. Louis, MO: Elsevier Inc.
  3. Wabuyele SL, McMillin GA (). Quantitation of Ethyl β-D-glucuronide in Human Umbilical Cord Tissue by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). In Langman LJ, Snozek CLH (Eds.), Clinical Applications of Mass Spectrometry Methods and Protocols, Methods in Molecular Biology (2nd, 1383, pp. 69-78). Humana Press.
  4. Wu F, Scroggin TL, McMillin GA (). Detection of In Utero Cannabis Exposure in Umbilical Cord Tissue by A Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method. In Langman LJ, Snozek CLH (Eds.), Clinical Applications of Mass Spectrometry Methods and Protocols, Methods in Molecular Biology (2nd). Humana Press.
  5. McMillin GA (). Pharmacogenetics. In Clarke W (Ed.), Contemporary Practice in Clinical Chemistry (3rd). American Association for Clinical Chemistry.
  6. McMillin GA, Krasowski MD (). Therapeutic Drug Monitoring of Newer Anti-Epileptic Drugs. In Dasgupta A and Clarke WC (Eds.), TDM in Special Populations and Newer Applications. Elsevier.
  7. Marin SJ, McMillin GA (). Quantitation of Total Buprenorphine and Norbuprenorphine in Meconium by LC-MS/MS. In Garg U and Hammett-Stabler CA (Eds.), Clinical Applications of Mass Spectrometry Methods and Protocols, Methods in Molecular Biology (1383, pp. 59-68). Humana Press.
  8. Johnson-Davis, McMillin GA (). Application of Liquid Chromatography Combined with Mass Spectrometry or Tandem Mass Spectrometry for Therapeutic Drug Monitoring of Immunosuppressants. In Oellerich M and Dasgupta A (Eds.), Personalized Immunosuppression in Transplantation: Role of Therapeutic Drug Monitoring, Pharmacogenomics and Biomarkers Monitoring. Elsevier.
  9. Marin SJ, McMillin GA (). Quantitation of Buprenorphine, Norbuprenorphine, Buprenorphine Glucuronide, Norbuprenorphine Glucuronide and Naloxone in Urine by LC-MS/MS. In Garg U and Hammett-Stabler CA (Eds.), Clinical Applications of Mass Spectrometry Methods and Protocols, Methods in Molecular Biology (1383, pp. 69-78). Humana Press.
  10. Burtis C, Bruns D, Roberts W, McMillin GA (). Reference Information for the Clinical Laboratory and Therapeutic Drugs. In Burtis CA and Bruns DE (Eds.), Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics (7th Ed., pp. 951-94). St. Louis, MO: Elsevier Saunders.
  11. Snozek CLH, McMillin GA, Moyer TP (). Therapeutic Drugs and Their Management. In Burtis CA and Bruns DE (Eds.), Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics (7th Ed., pp. 536-58). St. Louis, MO: Elsevier Saunders.
  12. McMillin GA (). Pharmacogenetics. In Burtis CA and Bruns DE (Eds.), Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics (7th Ed., pp. 885-98). St. Louis, MO: Elsevier Saunders.
  13. McMillin GA, Johnson-Davis KL (). Issues of interferences in therapeutic drug monitoring. In Dasgupta A and Sepulveda JL (Eds.), Accurate Results in the Clinical Laboratory: A Guide to Error Detection and Correction (pp. 195-212). India: Newnes.
  14. McMillin GA, Keil DK, Strathmann FG (). Lead Testing. In Kwong TC, Magnani B, Rosano TG, Shaw LM (Eds.), The Clinical Toxicology Laboratory, Contemporary Practice of Poisoning Evaluation (2nd, pp. 319-34). Washington DC: AACC Press.
  15. Johnson-Davis KJ, Juenke JM, Davis R, McMillin GA (). Quantification of tricyclic antidepressants using UPLC-MS/MS. In Langman L, Snozek CLH. (Eds.), Methods in Molecular Biology (902) LC-MS in Drug Analysis (pp. 175-84). India: Springer.
  16. Snozek CLH, McMillin GA, Moyer TP (). Therapeutic Drugs and Their Management. In Burtis CA, Ashwood EA, Bruns DE. (Eds.), Tietz Textbook of Clinical Chemistry and Molecular Diagnosis (5th Ed., pp. 1057-108). St. Louis, MO: Elsevier Saunders.
  17. McMillin GA (). Pharmacogenetics. In Burtis CA, Ashwood EA, Bruns DE. (Eds.), In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (5th Ed., pp. 1339-70). St. Louis, MO: Elsevier Saunders.
  18. Roberts W, McMillin GA, Burtis CA, Bruns DE (). Reference Information for the Clinical Laboratory. In Burtis CA, Ashwood EA and Bruns DE. (Eds.), Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (5th Ed., pp. 2131-88). St. Louis, MO: Elsevier Saunders.
  19. Johnson-Davis K, McMillin GA (2010). Clinical Enzymology. In Bishop ML, Fody EP, Schoeff LE (Eds.), Clinical Chemistry: Principles, Procedures, Correlation (6th Edition, pp. 281-308). Baltimore: Lippincott, Williams & Wilkins.
  20. Juenke J, McMillin GA (2010). Analytical Support of Anticonvulsant Drug Monitoring: Beyond the Immunoassay. In Dasgupta A (Ed.), Advances in Chromatographic Techniques (pp. 85-101). Boca Raton FL: CRC Press.
  21. Marin S, McMillin GA (2009). LC-MS/MS Analysis of 13 Benzodiazepines and Metabolites in Urine, Serum, Plasma and Meconium. In Hammett-Stabler C, Garg U (Eds.), Clinical Applications of Mass Spectrometry (pp. 89-105). Totowa NJ: Humana Press.
  22. McMillin GA, Melis R, Bornhorst J (2009). Alcohol Abuse and Dependency: Genetics of Susceptibility, and Pharmacogenetics of Therapy. In Dasgupta A (Ed.), In: Critical Issues in Alcohol and Drugs of Abuse Testing (pp. 13-27). Washington DC: AACC Press.
  23. Stone J, McMillin G, Erickson C, Kwong TC (2008). Analytical and Clinical Toxicology. In Wu A (Ed.), Self-Assessment in Clinical Laboratory Science II (pp. 265-93). Washington, DC: AACC Press.
  24. Moyer T, McMillin GA, Shaw L (2008). Therapeutic Drugs In: Tietz Fundamentals of Clinical Chemistry. In Burtis C, Ashwood E, Bruns D. (Eds.), Tietz Fundamentals of Clinical Chemistry (pp. 539-61). St. Louis, MO.: Elsevier Saunders.
  25. Burtis C, Bruns D, Roberts W, McMillin GA (2008). Reference Information for the Clinical Laboratory and Therapeutic Drugs. In Burtis C, Ashwood E, Bruns D. (Eds.), Tietz Fundamentals of Clinical Chemistry (6th, pp. 836-73). St. Louis, MO: Elsevier Saunders.
  26. McMillin GA, Bornhorst JA (2008). Toxic Element Testing with Clinical Specimens. In Dasgupta A (Ed.), Handbook of Drug Monitoring Methods (pp. 263-82). Totowa, NJ: Humana Press.
  27. McMillin GA (2007). Pharmacogenetics. In Burtis C, Ashwood E, Bruns D (Eds.), Tietz Fundamentals of Molecular Diagnostics (6th, pp. 197-215). St. Louis, MO: Elsevier Saunders.
  28. McMillin GA, Hammett-Stabler CA (2006). Therapeutic Drug Monitoring. In: Contemporary Practice in Clinical Chemistry. In Clarke W, Dufour DR (Eds.), Tietz Textbook of Clinical Chemistry & Molecular Diagnostics (2nd , pp. 453-64). Elsevier Saunders .
  29. Hammett-Stabler CA, McMillin GA (2006). Toxicology and the Clinical Laboratory. In: Contemporary Practice in Clinical Chemistry. In Clarke W, Dufour DR (Eds.), Contemporary Practice in Clinical Chemistry (2nd Edition , pp. 453-64). American Association for Clinical Chemistry.
  30. McMillin GA, Linder MW, Bukaveckas BL (2005). Pharmacogenetics. In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. In Elsevier Saunders (Ed.), Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (4th Edition, pp. 1589-1616.).
  31. Burtis C, Bruns D, Roberts W, McMillin GA (2005). Reference Information for the Clinical Laboratory. In Elsevier Saunders (Ed.), Tietz Textbook of Clinical Chemistry and Molecular Diagnosis (4th Ed., pp. 2304-2316). Elsevier Saunders.
  32. Krefetz R, McMillin G (2004). Clinical Enzymology. In Bishop M, Fody N, Schoeff L (Eds.), Clinical Chemistry: Principles, Procedures, Correlation (5th Edition). Lippincott, Williams & Wilkins.
  33. White HS, Skeen GA, Edwards JA (1993). Characterization of Voltage-Sensitive Calcium Channels of Astrocytes Using the Fluorescent Probe Indo-1. In Scriabine A, Janis RA, Triggle DJ (Eds.), Drugs in Development (2, pp. 135-142). Branford, Connecticut: Neva Press.
  34. White HS, Skeen GA, Edwards JA (1992). Pharmacological Regulation of Astrocytic Calcium Channels: Implications for the Treatment of Seizure Disorders. In Yu ACH, Hertz L, Nirenberg MD, Sykova E, Waxman SG (Eds.), Progress in Brain Research, Neuronal-Astrocytic Interactions: Implications for Normal and Pathological CNS Function (94, pp. 77-87). Amsterdam: Elsevier.

Commentary

  1. McMillin GA (). Expert Commentary on CLINCHEM/2011/179507 Violent Behavior and Hallucination in a 32-Year Old Patient. Clin Chem, 59(4), 616.

Letter

  1. Juenke JM, Brown PI, Urry FM, Johnson-Davis KL, McMillin GA (2013 Aug 23). Simultaneous UPLC-MS/MS assay for the detection of the traditional antipsychotics haloperidol, fluphenazine, perphenazine, and thiothixene in serum and plasma [Letter to the editor]. Clin Chim Acta, 423, 32-4.
  2. Juenke JM, McGraw JP, McMillin GA, Johnson-Davis KL (2012 Feb 18). Performance characteristics and patient comparison of the ARK Diagnostics levetiracetam immunoassay with an ultra-high performance liquid chromatography with tandem mass spectrometry detection method [Letter to the editor]. Clin Chim Acta, 413(3-4), 529-31.

Abstract

  1. Metz TD, Silver RM, McMillin GA, Allshouse AA, Mansfield C, Heard K, Kinney GL, Wymore E, Binswanger IA (). Maternal marijuana exposure by self-report and umbilical cord sampling in a state with legalization. [Abstract] [Abstract]. Society for Maternal-Fetal Medicine.
  2. Scroggin T, Wu, F, Metz TD, Allshouse AA, Binswanger I, McMillin GA (). Detection of in utero Exposure to Cannabis, What Are We Missing? [Abstract] [Abstract]. The Association for Mass Spectrometry: Applications to the Clinical Lab Annual Meeting.
  3. Wabuyele SL, McMillin GA (). Evaluation of Solid Phase Extraction (SPE) Compared to Supported Liquid Extraction (SLE+) as Sample Preparation Techniques for LC-Ms/MS Detection of 49 Drugs and Metabolites in Umbilical Cord Tissue. [Abstract] [Abstract]. The Society of Forensic Toxicologists.
  4. Scroggin T, Wu F, McMillin GA (). Extraction Optimization for LC-MS/MS Quantification of Cannabinoids and Metabolites in Umbilical Cord Tissue and Meconium. [Abstract] [Abstract]. The Society of Forensic Toxicologists.
  5. Melis R, Mohamed J, Ha Y, Lyon E, McMillin GA (). Post-mortem CYP2D6 Genotyping and Copy Number Determinations Using DNA Extracted from Archived FTA Bloodstains [Abstract].
  6. Wu F, Scroggin TL, McMillin GA (). Detection of In-Utero Marijuana Exposure Using Umbilical Cord Tissue by LC-MS/MS [Abstract]. Academy of Clinical Laboratory Physicians and Scientists.
  7. Gage BF, Bass A, Lin H, Woller S, Stevens SM, Al-Hammdi N, Li J, Rodrigues T, Miller JP, McMillin G, Pendleton R, Jaffer A, King C, DeVore B, Porche-Sorbet R, Napoli L, Merrit K, Joykutty A, Hyun G, Anderson J, Hollomon W, Barrack R, Nunley R, Moskowitz G, Davila-Roman V, Eby C (). Genetics InFormatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis: Improvement in Time Spent in the Therapeutic INR Range [Abstract]. International Society on Thrombosis and Haemostasis.
  8. Gage BF, Bass A, Lin H, Woller S, Stevens SM, Al-Hammdi N, Li J, Rodrigues T, Miller JP, McMillin G, Pendleton R, Jaffer A, King C, DeVore B, Porche-Sorbet R, Eby C (). Genetics InFormatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis: Safety of a Target INR of 1.8. Presented at the Anticoagulation Forum [Abstract].
  9. Wabuyele SL, McMillin GA (). Quantitative Analysis of Ethyl Glucuronide in Human Umbilical Cord Tissue by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) [Abstract]. American Association for Clinical Chemistry.
  10. Wabuyele SL, McMillin GA (). Quantitative Analysis of Ethyl Glucuronide in Human Umbilical Cord Tissue by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) [Abstract] [Abstract]. American Association for Clinical Chemistry.
  11. Tantravahi SK, McMillin GA, Clair PM, Sadler AJ, Dowel T, Geier J, Bernanrd PS, Deininger MW (). Evaluation of an Automated Immunoassay for Quantification of Imatinib in Plasma. [Abstract] [Abstract]. American Society of Hematology.
  12. Wu F, Melis R, McMillin GA (). Application of Matrix Assisted-Laser Desorption Ionization Time-of-Flight Mass Spectrometry for CYP2D6 Genotype and Copy Number Analysis [Abstract]. American Association for Clinical Chemistry.
  13. Gage BF, Bass A, Lin H, Woller S, Stevens SM, Al-Hammdi N, Li J, Rodrigues T, Miller JP, McMillin G, Pendleton R, Jaffer A, King C, DeVore B, Porche-Sorbet R, Eby C (). Genetics InFormatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis: Benefit of Pharmacogenetic Dosing. Presented at the Anticoagulation Forum [Abstract].
  14. Wu F, Melis R, McMillin GA (). Application of Matrix Assisted-Laser Desorption Ionization Time-of-Flight Mass Spectrometry for CYP2D6 Genotype and Copy Number Analysis [Abstract] [Abstract]. American Association for Clinical Chemistry.
  15. Scroggin TL, Rasmussen NN, McMillin GA (). Quantitation of Cocaine and Metabolites, Barbiturates, and Phencyclidine in Meconium by LC-MS/MS [Abstract]. The Society of Forensic Toxicologists.
  16. Hill BM, Marin SJ, McMillin GA (). ELISA with Reflex to LC-MS/MS for Detection and Quantitation of Buprenorphine and Norbuprenorphine in Serum or Plasma [Abstract]. The Society of Forensic Toxicologists.
  17. Leung EY, Agolini E, Melis R, McMillin G, Friedman PN, Peterson P, Danahey K, ODonnell PH, Yeo J (). Evaluation of the Invader Genotyping and TaqMan Copy Number Variation Assays for CYP2D6 [Abstract]. The American Association for Clinical Chemistry Annual Meeting.
  18. Wu F, Marin SJ, Clark CJ, McMillin GA (). Stability of 21 Cocaine, Opioid and Benzodiazepine Drug Analytes in Meconium at Three Temperatures [Abstract]. The Academy of Clinical Laboratory Physicians and Scientists Annual Meeting.
  19. Auger S, Marin S, McMillin G, Birsan A, Lacoursiere J, Picard P (). Meconium Targeted Drug Screening in 9 Seconds per Sample Using Laser Diode Thermal Desorption Mass Spectrometry (LDTD-MS/MS) [Abstract]. The American Society of Mass Spectrometry Annual Meeting.
  20. Melis R, Johnson-Davis K, Paul E, McMillin GA (). Implementation of the OpenArray Genotyping Platform in a Clinical Thiopurine-s-Methyltransferase (TPMT) Genotype-Phenotype Study [Abstract]. The American College of Medical Genetics Annual Meeting.
  21. Kalman LV and the PGx Nomenclature Workgroup (). Pharmacogenetic Allele Nomenclature: International Workgroup Recommendations for Test Result Reporting [Abstract]. The American College of Medical Genetics Annual Meeting.
  22. Picard P, Marin SJ, McMillin GA, Birsan A, Auger S, Lacoursiere J (). Meconium Targeted Drug Screening in 9 Seconds per Sample Using Laser Diode Thermal Desorption Mass Spectrometry (LDTD-MS/MS) [Abstract]. The Association for Mass Spectrometry: Applications to the Clinical Lab Annual Meeting.
  23. Johnson-Davis KL, Melis R, McMillin GA (). Genotype-Phenotype Relationship of Inosine Triphosphate Pyrophosphatase (ITPA) among Normal and Abnormal Thiopurine-S-Methyltransferase (TPMT) Activity Samples [Abstract]. The International Therapeutic Drug Monitoring and Clinical Toxicology Congress.
  24. Powers JL, Melis R, Malmberg E, Johnson-Davis K, Buys S, Lyon E, McMillin GA (). Impact of Multiple CYP Variants on Tamoxifen Metabolite Concentrations [Abstract]. The Academy of Clinical Laboratory Physicians and Scientists Annual Meeting, and recognized with a Young Investigator Award.
  25. Williams JA, Marin SJ, Chittamma A, Clark C, McMillin GA (). Umbilical Cord Tissue: An Ideal Candidate for Detection of in utero Marijuana Exposure [Abstract]. The Association of Clinical Scientists Annual Meeting.
  26. Powers JL, Melis R, Malmberg E, Johnson-Davis K, Buys S, Lyon E, McMillin GA (). Impact of Multiple CYP Variants on Tamoxifen Metabolite Concentrations [Abstract]. The Association of Clinical Scientists Annual Meeting.
  27. Marin SJ, McMillin GA, Strathmann FG (). Is it Noroxymorphone or Nornaloxone, and Why Should You Care? [Abstract]. The Mass Spectrometry: Applications to the Clinical Lab Annual Meeting.
  28. McDonald KR, Brewer WE, Cabrices OG, Kemnitzer W, Morgan SL, Marin SJ, McMillin GA, Patton JS (). Fast Simple Method for the Analysis of Benzodiazepines in Meconium and an Interlaboratory Method Comparison [Abstract]. The Mass Spectrometry: Applications to the Clinical Lab Annual Meeting.
  29. Marin SJ, Metcalf A, McMillin GA (). Comparison of Methods for Extraction of Drugs from Umbilical Cord Tissue [Abstract]. The Society for Forensic Toxicology Annual Meeting.
  30. Linakis MW, Campbell SC, Stockmann C, Johnson-Davis KL, McMillin GA, Balch AH, Sherwin CMT, Spigarelli MG (). Frequency of Thiopurine Metabolite Tests with Clinically Important Results Requiring Modifications to Therapy [Abstract]. The American Academy of Pediatrics Annual Meeting.
  31. Linakis MW, Campbell SC, Stockmann C, Johnson-Davis KL, McMillin GA, Sherwin CMT, Spigarelli MG (). Regional Differences in Thiopurine Methyltransferase Activity [Abstract]. The American Academy of Pediatrics Annual Meeting.
  32. Campbell SC, Johnson-Davis KL, Linakis MW, McMillin GA, Sherwin CMT, Spigarelli MG (). Evaluating the Relationship of Age and Thiopurine Methyltransferase Activity [Abstract]. The American Academy of Pediatrics Annual Meeting.
  33. McMillin GA, Marin SJ, Johnson-Davis KL, Lawlor BG, Strathmann FG (). An Alternative Strategy for Pain Management Compliance Testing using a Combination of Immunoassay and Time-of-Flight Mass Spectrometry [Abstract]. The Pain Week.
  34. Hopkins ML, Malmberg E, Church B, McMillin GA (). Choosing the Best Urine Benzo Screen for Monitoring Adherence to Alprazolam or Clonazepam [Abstract]. The Pain Week.
  35. Campbell SC, Johnson-Davis KL, Linakis MW, Roberts JK, McMillin GA, Sherwin CMT, Spigarelli MG (). Evaluating the Relationship of Age and Thiopurine Methyltransferase Activity [Abstract]. The Pediatric Academic Societies Annual Meeting.
  36. Campbell SC, Johnson-Davis KL, McMillin GA, Sherwin CMT, Spigarelli MG (). Trends of Pediatric and Adolescent TPMT Pharmacogenomic Testing [Abstract]. The Pediatric Academic Societies Annual Meeting.
  37. Lawlor BG, Marin SJ, Chittamma A, Clark CJ, McMillin GA (). Development of a qualitative urine drug panel by liquid chromatography time of flight mass spectrometry (LC-TOF-MS) [Abstract]. Submitted for presentation at the International Therapeutic Drug Monitoring and Clinical Toxicology Congress in September 2013.
  38. Marin SJ, Metcalf A, McMillin GA (). Detection of utero drug exposure using umbilical cord tissue and liquid chromatography time-of-flight mass spectrometry (TOF) [Abstract]. Submitted for presentation at the International Therapeutic Drug Monitoring and Clinical Toxicology Congress in September 2013.
  39. Rasmussen NN, Marin SJ, Clark CJ, McMillin GA (). Detection of 57 Drugs and Metabolites in Meconium by Liquid Chromatography-Time of Flight Mass Spectrometry [Abstract]. Submitted for presentation at the International Therapeutic Drug Monitoring and Clinical Toxicology Congress in September 2013.
  40. Campbell SC, McMillin GA, Sherwin CMT, Spigarelli MG (). Utilization of thiopurine methyltransferase pharmacogenomics testing [Abstract]. Submitted for presentation at the International Therapeutic Drug Monitoring and Clinical Toxicology Congress in September 2013.
  41. Williams JA, Marin SJ, Chittamma A, Clark CJ, McMillin GA (). Detection of in utero marijuana exposure by three methods using umbilical cord tissue [Abstract]. Submitted for presentation at the International Therapeutic Drug Monitoring and Clinical Toxicology Congress in September 2013.
  42. Green AA, Campbell SC, Sherwin CMT, McMillin GA, Spigarelli MG (). Pharmacogenomic testing trends in pediatric patients [Abstract]. To be presented at the Pediatric Academic Societies annual meeting in May 2013.
  43. Juenke JM, McMillin GA, Johnson-Davis KL (). Application of ultra high liquid chromatography tandem mass spectrometry to the analysis of tamoxifen and metabolites in serum and plasma to support a genotyping study [Abstract]. Presented at the Mass Spectrometry: Applications to the Clinical Lab annual meeting in February.
  44. Clark ZD, Strathmann FG, McMillin GA (). Diluting & shooting yourself in the foot: complications with sample-to-sample variations in signal suppression [Abstract]. Presented at the Mass Spectrometry: Applications to the Clinical Lab annual meeting in February.
  45. Strathmann FG, Marin SJ, McMillin GA (). Screen, reflex, confirm, repeat: is that the best we can do for pain management testing? [Abstract]. Presented at the Mass Spectrometry: Applications to the Clinical Lab annual meeting in February.
  46. Melis R, Pont-Kingdon G, Lyon E, McMillin GA (). Haplotyping two ITPA variants associated with reduced incidence of ribavirin-induced anemia [Abstract]. Presented at the Personal Genomes and Medical Genomics conference in November.
  47. Campbell SC, Sherwin CMT, McMillin GA, Spigarelli MG (). Understanding the use and trends of pharmacogenomic testing [Abstract]. Presented at the American Association of Pharmaceutical Sciences in October.
  48. Johnson-Davis KL, Juenke JM, Jensen L, Clark C, Brown PI, McMillin GA (). Retrospective study of false positive rates for urine drug screening by immunoassay [Abstract]. Presented at the Pain Week annual meeting in September.
  49. Melis R, McMillin G, Lyon E, Slev P (). IL28B genotype for predicting HCV treatment response and technical limitations involving rare variants [Abstract]. Presented at the Association of Medical Laboratory Immunologists meeting in August.
  50. Yang L, Gaweda AE, Reynolds KK, McMillin G, Brier M, Valdes R, Linder MW (). Prediction of INR response based on CYP2C9 and VKORC1 genotypes [Abstract]. Presented at the American Association for Clinical Chemistry annual meeting in July.
  51. Lin C, Nelson G, McMillin GA (). Evaluation of the NexScreen and DRUGCHECK Waive urine drug detection cups [Abstract]. Presented at the American Association for Clinical Chemistry annual meeting in July.
  52. Barakauskas VE, Davis R, Krasowski MD, McMillin GA (). Detection of THC in infant urine – truth or fallacy? [Abstract]. Presented at the Academy of Clinical Laboratory Physicians and Scientists annual meeting in June.
  53. Lin C, McMillin GA, Strathmann FG (). Zinc: a possible interference in drug testing [Abstract]. Presented at the Academy of Clinical Laboratory Physicians and Scientists annual meeting in June, and recognized with a Young Investigator.
  54. Travis J, Strathmann FG, McMillin GA (). Elemental interference attributed to iodine in human urine [Abstract]. Presented at the Winter Conference on Plasma Spectrochemistry in January.
  55. Clark ZD, Strathmann FG, McMillin GA (). Urine profiles of oxycodone, noroxycodone, oxymorphone, and noroxymorphone [Abstract]. Presented at the Mass Spectrometry: Applications to the Clinical Lab annual meeting in January.
  56. Juenke JM, Thomas RL, Brown PI, McMillin GA, Johnson-Davis KL (). Application of ultra high pressure liquid chromatography tandem mass spectrometry to the analysis of antiarrhythmic drugs in serum and plasma [Abstract]. Presented at the joint meeting of the Society of Forensic Toxicologists and the International Association of Forensic Toxicologists in September.
  57. Haglock CJ, Moody DE, McMillin GA (). Statistical analysis of markers for nicotine exposure in urine specimens [Abstract]. Presented at the joint meeting of the Society of Forensic Toxicologists and the International Association of Forensic Toxicologists in September.
  58. Juenke JM, Thomas RL, Brown PI, McMillin GA, Johnson-Davis KL (). Application of ultra high pressure liquid chromatography tandem mass spectrometry to the analysis of antiarrhythmic drugs in serum and plasma [Abstract]. Presented at the joint meeting of the Society of Forensic Toxicologists and the International Association of Forensic Toxicologists in September.
  59. Carlisle HJ, Davis R, Moody DE, Clark C, McMillin GA (). Patterns of buprenorphine and metabolites,with and without naloxone in human urine [Abstract]. Presented at the joint meeting of the Society for Forensic Toxicologists and the International Assocation of Forensic Toxicologists, September.
  60. De S, Jimenez E De BK, Johnson-Davis KL, McMillin GA (). Analytical performance characteristics of the Abbott Architect i2000 sirolimus assay comparisons with liquid chromatography tandem mass spectrometry (LC-MS/MS) and Abbott IMX methods [Abstract]. Presented at the American Association for Clinical Chemistry Annual Meeting, July.
  61. Johnson-Davis KL, Juenke JM, McGraw JP, Miller KA, Ford MA, Anderson BL, Wienhoff KA, McMillin GA (). Evaluation of ARK Diagnostics immunoassays for gabapentin, lamotrigine, levetriacetam, topiramate, and zonisamide on the Beckman AU400e chemistry analyzer [Abstract]. Presented at the American Association for Clinical Chemistry Annual Meeting, July.
  62. Juenke JM, Brown PI, McMillin GA, Johnson-Davis KL (). Catachem ethylene glycol assay: utility in the laboratory [Abstract]. Presented at the American Society for Clinical Pathology annual meeting in October.
  63. Clinton SR, Lawler BG, Carlisle H, Davis R, McMillin GA (). Suspected patient adulteration of urine by ex vivo addition of oxycodone and buprenorphine containing formulations [Abstract]. Presented at the Academy of Clinical Laboratory Physicians and Scientists annual meeting in June, and recognized with a Young Investigator Award.
  64. Borgman MP, Linder WT, Reynolds KK, McMillin GA, Pendleton RC, Valdes R, Linder MW (). Prospective validation of plasma s-warfarin concentration-time profiles adjusted for CYP2C9 genotype [Abstract]. Presented at the American Association for Clinical Chemistry Annual Meeting, July.
  65. Melis R, Lewis T, McMillin GA, Lyon E, Slev P, Swenson J (). CNV and incomplete linkage disequilibrium interference with the HCP5 genotyping assay for Abacavir hypersensitivity [Abstract]. Presented at the Association for Molecular Pathology Annual Meeting, November.
  66. Lee CC, McMillin GA, Melis R, Babic N, Yeo KTJ (). Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics INFINITI™ and Luminex CYP2C19 panels [Abstract]. Presented at the American Association for Clinical Chemistry Annual Meeting July.
  67. Lin C, Wilson A, Church BB, Ehman S, Roberts WL, McMillin GA (). Pediatric reference intervals for serum copper and zinc [Abstract]. Presented at the Academy of Clinical Laboratory Physicians and Scientists Annual Meeting in June.
  68. Linder MW, Pendleton RC, Reynolds KK, McMillin GA, Valdes R, Wilson A (). Results from a randomized control pilot trial of PerMIT: warfarin [Abstract]. Presented at the 11th National Conference on Anticoagulation Therapy in May.
  69. Melis R, Faucon C, McMillin GA, Lyon E, Slev P (). Rapid detection of two variants near the IL28B locus associated with HCV clearance and treatment response [Abstract]. Clinical Chemistry, 56(S6), A89.
  70. Greene DN, Carlisle H, Clark CJ, Thompson CD, Lehman M, McMillin GA (). Drugs of abuse: detection in a cup [Abstract]. Clinical Chemistry, 56(S6), A162-3.
  71. Marin SJ, Roberts M, Davis R, McMillin GA (). Analysis of 21 benzodiazepines, Zolpidem and Zopiclone in serum or plasma using UPLC/MS/MS with liquid-liquid extraction [Abstract]. Clinical Chemistry, 56(S6), A234.
  72. Hardy LB, Fan SL, Pistorino AM, Juenke JM, McMillin GA, Horowitz GL (). Ethylene glycol screening: adapting the CATCHEM enzymatic assay to minimize false postiives [Abstract]. Clinical Chemistry, 56(S6), A230.
  73. Roberts M, Marin SJ, McMillin G, Wood M (). A quantitative UPLC/MS/MS assay for 21 benzodiazepine drugs, zolpidem and zopiclone in serum [Abstract]. Presented at the Society of Forensic Toxicologists Annual Meeting October.
  74. Thompson C, Clark C, McMillin GA, Lehman C, Johnson-Davis K (). Evaluation of two chemistry analyzers for urine drug screen testing in the emergency department [Abstract]. Clinical Chemistry, 56(S6), A238.
  75. Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin J, Kim H, Angchaisuksiri P, Glynn RJ, Chen J, Carlquist JF, Grice GR, Kronquist KE, Gage BF (). Warfarin dosing algorithm refinements after 6-11 days of therapy based on pharmacogenetic, pharmacokinetic, clinical, and laboratory data [Abstract]. Presented at the American College of Cardiology Annual Meeting.
  76. Melis R, Millson A, Glezos C, Watkins WS, McMillin GA, Lyon E, Slev P (). Design and optimization of a simple screening assay for prediction of hypersensitivity reaction to abacavir [Abstract]. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI) Annual Meeting.
  77. Melis R, FAuron C, McMillin G, Lyon E, Hubley LM, Slev PR (). Genotype frequency of two polymorphisms: rs12979860 and rs8099917 near the IL28B locus associated with HCV clearance and treatment responses in different ethnic groups [Abstract]. Presented at the Pan Amercian Society for Clinical Virology in May.
  78. Roberts M, Marin SJ, McMillin G, Wood M (). Quantitative analysis of 21 benzodiazepine drugs, zolpidem and zopiclone in serum [Abstract]. Presented at the International Association of Forensic Toxicologists Annual Meeting, August.
  79. Johnson-Davis KL, Juenke JM, Brown PL, McMillin GA (). Simultaneous UPLC-MS/MS assay for the detection of Levetriacetam and Gabapentin in serum and plasma [Abstract]. Clinical Chemistry, 56(S6), A228.
  80. Marin SJ, Christensen RD, Baer VL, Merrell M, McMillin GA (). Comparison of nicotine and nicotine metabolite concentrations in paired specimens of meconium and umbilical cord tissue, and correlation with maternal smoking histories [Abstract]. Clinical Chemistry, 56(S6), A234.
  81. Rasmussen N, Juenke JM, Marin SJ, Merrell M, McMillin GA (2009). Evaluation if immunalysis immunoassays for detection of buprenorphine, oxycodone, meperidine, and tramadol in urine by EMIT. [Abstract]. Society of Forensic Toxicology Annual Meeting.
  82. Clark CJ, Garn JV, Marin SJ, Davis R, Merrell M, McMillin GA (2009). Comparison of Fisher Tisuemiser® and Bullet Blender™ in homogenizing meconium for drugs testing [Abstract]. Society of Forensic Toxicology Annual Meeting.
  83. Marin SJ, Hughes J, Clark C, Merrell M, McMillin GA (2009). Targeted drug screening using ultrafast HPLC coupled with high-definition accurate-mass TOF-MS [Abstract]. Society of Forensic Toxicology Annual Meeting.
  84. Marin SJ, Yue B, Cottam B, Rockwood A, McMillin GA (2009). Determination of nicotine and metabolites in urine, serum, plasma and meconium by liquid chromatography tandem mass spectrometry (LC-MS/MS) [Abstract]. Therapeutic Drug Monitoring, 31(5), 627.
  85. De BK, Jimenez E, Sawyer JC, McMillin GA (2009). Analytical performance characteristics of tacrolimus assay in Abbott Architect i2000 and its comparison to LC-MS/MS [Abstract]. Clinical Chemistry, 55(S6), A252.
  86. Johnson-Davis KL, Juenke J, McMillin G (2009). Therapeutic drug monitoring of busulfan using an automated chemistry analyzer [Abstract]. Clinical Chemistry, 55(S6), A248.
  87. Davis R, Marin SJ, McMillin GA (2009). 11-Nor-delta-9-carboxy-tetrahydrocannabinal analysis in urine, serum and plasma by UPLC-MS/MS [Abstract]. Clinical Chemistry, 55(S6), A264.
  88. Salamone SJ, Clarke W, Hammett-Stabler C, McMillin G, Johnson-Davis K, Fleisher M, Courtney JB, Benfield C, Harney RL, Kozo D, Li Y, Lundell GD (2009). A multicenter evaluation of a novel nanoparticle assay to quantitate busulfan in plasma [Abstract]. Clinical Chemistry, 55(S6), A266-7.
  89. Marin SJ, Juenke JM, Johnson-Davis KL, McMillin GA (2009). Validation of a new immunoassay for quantification of topiramate. [Abstract]. Clinical Chemistry, 55(S6), A252.
  90. Johnson-Davis KL, Ford CD, Petersen FB, McMillin GA (2009). Should busulfan dose adjustments be made based on first dose pharmacokinetics? [Abstract]. Academy of Clinical Laboratory Physicians and Scientists Annual Meeting.
  91. Juenke JM, Ford MA, Brown PL, McMillin GA (2008). A rapid screen for ethylene glycol: evaluation of the CATACHEM ethylene glycol enzymatic assay performed with the Olympus AU400e [Abstract]. Clinical Chemistry.
  92. Travis JJ, Hunt W, Rockwood AL, McMillin GA (2008). Fractionation of five arsenic species by HPLC-ICP-MS [Abstract]. Clinical Chemistry.
  93. Johnson-Davis K, Juenke JM, Pickering JW, McMillin GA (2008). An enzymatic assay used to identify patients with low thiopurine s-methyltransferase (TPMT) activity [Abstract]. Clinical Chemistry.
  94. Johnson-Davis K, Melis R, Lyon E, Juenke JM, McMillin GA (2008). Genotype-phenotype relationship thiopurine s-methyltransferase (TPMT) in a reference population [Abstract]. Academy of Clinical Laboratory Physicians & Scientists Meeting.
  95. Coles R, Kushnir MM, McMillin GA, Urry FM (2008). Validation of SPEW are columns for drugs of abuse analysis in urine, serum, plasma, whole blood, and meconium [Abstract]. Clinical Chemistry, 54(S6), A10.
  96. Melis R, Wilson A, Glezos C, Pendelton RC, Lyon E, McMillin GA (2008). Prospective pharmacogenetic-based warfarin dosing in orthopedic patients [Abstract]. Cold Sping Harbor Pharmacogenomics Symposium.
  97. Davis R, Marin S, McMillin GA (2008). Opiate analysis in urine, plasma and meconium by UPLC-MS/MS [Abstract]. Mass Spectrometry : Applications to the Clinical Laboratory Meeting.
  98. Pattison EG, Kushnir MM, Davis R, Sadjadi SA, Annesley TM, Rockwood AL, McMillin GA (2008). Rapid quantification of immunosuppressant drugs using dual column analysis and rapamycin-D3 [Abstract]. Mass Spectrometry: Applications to the Clinical Laboratory Meeting.
  99. Marin S, Merrell M, McMillin GA (2008). Application of a biochip microarray ELISA-based assay for drugs of abuse screening to meconium [Abstract]. Society of Forensic Toxicology Annual Meeting.
  100. Salamone SJ, Beumer JH, Egorin MJ, Hammett-Stabler C, McMillin G, Juenke J, Lepp S, Li Y, Courtney JB, Harney Rl, Lundell GD (2008). A multi-center evaluation of a rapid immunoassay to quantitate 5-fluorouracil in plasma [Abstract]. Hematology Oncology Pharmacy Association Annual Meeting.
  101. Travis JJ, Hunt JW, Rockwood AL, McMillin GA (2008). Quanification of five arsenic species in human urine by HPLC-ICP-MS [Abstract]. Plasma Spectrochemistry Conference (Winter Annual Meeting).
  102. Beumer JH, Egorin MJ, Milano G, Gamelin E, Boisdron-Celle M, Hammett-Stabler C, McMillin G, Lepp S, Salamone SJ, Li Y, Courtney JB, Harney RL, Lundell GD (2008). A rapid nanopartical immunoassay to quantitate 5-fluorouracil (5-FU) in plasma [Abstract]. American Society of Clinical Oncology (ASCO) GI.
  103. MacKay MW, Rusho B, Jackson D, Hunt JW, McMillin GA, Jones K, Winter B (2007). Pumping iron in a pediatric hospital: the physical and chemical stability of iron sucrose in parenteral nutrition [Abstract]. American Society of Health-System Pharmacists Mid-year Clinical Meeting.
  104. Marin S, Keith L, Merrell M, McMillin GA (2007). Comparison of drugs of abuse detection in meconium by ELISA and EMIT [Abstract]. Society of Forensic Toxicology Annual Meeting.
  105. Marin S, Merrell M, McMillin GA (2007). Confirmation of benzodiazepines in urine, serum, plasma and meconium by LC-MS/MS [Abstract]. Asolimar Conference associated with the American Society of Mass Spectrometry.
  106. Marin SJ, Coles R, Urry FM, McMillin GA (2007). Cannabinoid quantitation in meconium using two dimensional gas chromatography mass spectrometry [Abstract]. Clinical Chemistry, 53(6S), A103.
  107. Agarwal G, McMillin G, Salamone SJ, Courtney J, Lyons B, Harney RL, He S, Lundell G (2007). Evaluation of a rapid immunoassay for busulfan quantitation in plasma at two laboratories [Abstract]. Clinical Chemistry, 53, A101.
  108. Melis R, Lyon E, McMillin GA (2007). Evaluation of CYP2C9 and VKORC1 genotyping assays from Third Wave and Tm Biosciences for identification of warfarin sensitivity. [Abstract]. Clinical Chemistry, 53(S6), 153.
  109. Erdogan E, Urry FM, Miller M, Phansalkar AR, McMillin GA (2007). Differentiating opiate metabolism from independent opiate use based on proportions of non-glucuronidated opiates in urine [Abstract]. Clinical Chemistry, 53, 153.
  110. Yue B, Kushnir MM, McMillin G, Meikle AW, Rockwood AL, Marin SJ, Felix WD (2006). High throughput anaylsis of testosterone and immunosuppressants by elevated temperature LC with MS/MS detection [Abstract]. American Society of Mass Spectrometry Annual Meeting.
  111. Yang X, Janatova J, Juenke JM, McMillin G, Andrade JD (2006). Application of a one-step homogeneous immunoassay for quantitation of antiepileptic drugs (AEDs) [Abstract]. Oak Ridge Conference (Annual Meeting).
  112. Juenke JM, Ford MA, Brown PI, McMillin GA (2006). The Seradyn QMS® zonisamide immunoassay: an application protocol for the Olympus AU400e analyzer [Abstract]. Clinical Chemistry, 52(6S), A103.
  113. Ritchie JC, Berry D, Dugaw K, McMillin G, Wilson J (2006). Inter-laboratory comparison of serum lamotrigine methods [Abstract]. Clinical Chemistry, 52(6S), A65.
  114. Travis JJ and McMillin G (2006). Direct analysis of free copper in serum by ultracentrifugation and ICP-MS [Abstract]. Plasma Spectrochemistry Conference (Winter Annual Meeting).
  115. Allison A, McMillin G, Dasgupta A (2005). Mathematical model for estimating carbamazepine 10, 11-epoxide concentration in serum by using two carbamazepine immunoassays [Abstract]. American Journal of Clinical Pathology, 124, 453-4.
  116. Melis R, Lyon E, McMillin GA (2005). CYP2D6, CYP2C9, and CYP2C19 genotypes for multiple ethnic groups, using universal bead array technology [Abstract]. Clinical Chemistry, 51(6S), A:189.
  117. Melis R, Lowry MR, Schmidt LJ, Lyon E, McMillin GA (2005). CYP2D6, CYP2C9, and CYP2C19 genotyping of venlafaxine (Effexor®  treated patients, seeking correlation between genotype and metabolic phenotype [Abstract].
  118. Travis JJ, Urry FM, McMillin GA (2004). Method for the quantification of copper in liver tissue by inductively coupled plasma mass spectrometry [Abstract]. Clin Chem, 50(6S), A60-1.
  119. McMillin GA, Lowry MR, Schmidt LJ, Pickering JW, Lyon E (2004). Correlation of venlafaxine doses and serum concentrations with cytochrome P450 genotypes [Abstract]. Clin Chem, 50(6S), A128.
  120. Yue B, Rockwood AL, Kushnier MM, McMillin GA, Nelson G (2004). Fast analysis of everolimus in whole blood by simple column switching and tandem MS [Abstract]. Clin Chem, 50(6S), A134.
  121. McMillin GA, Travis JJ, Owen WE, Urry FM, Swenson S, Roberts WL (2004). Evaluation of the reference interval for free (nonceruloplasmin-bound) serum copper [Abstract]. Am J Clin Pathol, 122, 462.
  122. Juenke J, Brown P, Urry F, McMillin G (2004). Temperature stability of twelve therapeutic drugs in clinical laboratory specimens. [Abstract]. Clinical Chemistry, 50(6S), A137.
  123. Coles R, McMillin GA, Urry FM (2003). Misidentification of dextrorphan as levorphanol in urine by some gas chromatography-mass spectrometry methods [Abstract]. Clin Chem, 49(6), A122.
  124. McMillin GA, Pickering J, Gedge F, Lyon E (2003). Comparison of two methods for genotyping cytochrome P450 2C9 and 2C19 [Abstract]. Am J Clin Pathol, 120(2).
  125. Juenke JM, Brown PI, McMillin GA, Urry FM (2003). Modification of Abbott TDx cyclosporin monoclonal whole blood assay set up for 2 hour postdose monitoring [Abstract]. Lab Med, 34(6), 433.
  126. Juenke JM, Brown PI, McMillin GA, Urry FM (2003). The utility of interpretive comments to decrease the number of inappropriate free phenytoin orders [Abstract]. Lab Med, 34(6), 433.
  127. McMillin GA, Costa RA, Hunt JW, Urry FM (2003). Method for quantification of iron in urine and/or liver by DRC-ICP-MS [Abstract]. Clin Chem, 49(6), A142.
  128. Joos L, McMillin GA (2003). Use of inaccurate pipets in lead quantification by ICP-MS [Abstract]. Clinical Chemistry, 49(6), A91.
  129. McMillin GA, Owen WE, Lambert TL, Roberts WL (2002). DIGIBINDR and DigiFabR interference in five digoxin immunoassays [Abstract]. Am J Clin Pathol, 118(2), 295-6.
  130. Owen WE, McMillin G, Annesley TM, De BK, Bach PR, Roberts WL (2002). Effects of digibind on selected digoxin immunoassays [Abstract]. Clin Chem, 48(6), A41.
  131. McMillin GA, Owen WE, Juenke JM, Kent J, Roberts WL (2002). Potential of two digoxin selective fab products to interfere with digoxin immunoassays [Abstract]. Annals of Clinical Laboratory Science, 32(3), 318-319.
  132. Haven TR, Skeen GA, Wu LL, Skodack-Jones L, Carroll KC (2000). Improvement in mycoplasma pneumoniae culture medium [Abstract].
  133. Skeen GA, Wu LL, Pozharow V, Wu JT (1997). Development of a microplate ELISA to measure autoantibodies to oxidized LDL in human serum [Abstract]. Clin Chem, 43(6), S262.
  134. White HS, Brown D, Skeen GA, Wolf HH, Twyman RE (1995). The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents [Abstract]. Epilepsia, 36(S3), S39-40.
  135. Skeen GA, Wolf HH, White HS (1995). D-23129 attenuates glutamate-evoked whole-cell currents of mouse cortical neurons through an interaction with kainate-sensitive ion channels [Abstract]. The Journal of Neuroscience, 21(#145.22), 353.
  136. Skeen GA, Twyman RE, White HS (1994). The dihydropyridine nitrendipine reduces N-methyl-D-aspartate - (NMDA) evoked single - channel activity by a mechanism consistent with open channel block [Abstract]. The Journal of Neuroscience, 20, 1143.
  137. Filloux F, Fitts RC, Skeen GA, White HS (1993). Nitrendipine displaces [3H] binding throughout mouse brain [Abstract]. The Journal of Neuroscience, 19, 719.
  138. Skeen GA, White HS, Twyman RE (1993). Nitrendipine reduces NMDA/glycine-evoked single-channel currents in cultured mouse neurons [Abstract]. The Journal of Neuroscience, 19, 719.
  139. White HS, Hunt J, Skeen GA, Baron B, Kehne J, Whitten J, Salituro F, Harrison B, MacDonald IA, Palfreyman M (1992). The anticonvulsant action of strychnine-insensitive glycine antagonists is potentiated by probenecid [Abstract]. Seizure, 1(SA), P7/57.
  140. Skeen GA, White HS (1992). NMDA-induced calcium transients are attenuated by voltage-sensitive calcium channel antagonists [Abstract]. The Journal of Neuroscience, 18, 432.
  141. Skeen GA, White HS (1992). Voltage-sensitive calcium channel antagonists attenuate NMDA-evoked calcium influx [Abstract]. Seizure, 1(SA), P3/17.
  142. White HS, Skeen GA, Howell MC, Litzinger MA (1991). Astrocytes express a physiologically functional W-conotoxin binding site [Abstract]. American Society for Neurochemistry, 22, 101.
  143. Howell MC, Litzinger MA, Skeen GA, White HS (1991). Expression of [125I]w-conotoxin-sensitive binding site in mouse cortical astrocytes [Abstract]. The Journal of Neuroscience, 17(#462.7), 1161.
  144. Skeen GA, Wolf HH, Swinyard EA, White HS (1991). Flunarizine blocks KCl-induced Ca2+ influx into cerebellar granule cells through an effect on glutamate-gated Ca2+ channels [Abstract]. The Journal of Neuroscience, 17, 921.
  145. Brozoski TJ, Stenvers K, Athorp A, Skeen G, Brozoski EL, Oeth K, Green J (1991). Nigrostriatal dopaminergic activity, as determined by in vivo electrochemical detection during food consumption and conditioned consumatory behavior [Abstract]. The Journal of Neuroscience, 17, 131.14.
  146. Skeen G, Woodhead J, Wolf H, Swinyard E, Tietz E, White S (1990). Development of kindled seizures following electrical stimulation of the cornea [Abstract]. The Journal of Neuroscience, 16(#138.1), 307A.
  147. Smy L, McMillin G (). Urine buprenorphine and metabolite patterns in a large cohort of patients [Abstract]. American Association for Clinical Chemistry.
  148. Kim K, McMillin GA, Bernard PS, Walker BS, Schmidt R (). Cost-effectiveness of therapeutic drug monitoring for imatinib administration in patients with chronic myeloid leukemia.International Society for Pharmacoeconomics and Outcomes Research [Abstract].
  149. Smy L, McMillin GA (). Evaluation of imatinib concentrations in samples submitted for BCR-ABL1 testing – evidence to support therapeutic drug monitoring for dose optimization? [Abstract]. American Journal of Clinical Pathology.
  150. Gherasim C, Melis R, Donahue WL, McMillin (). Genotyping of selected alleles involved in tramadol metabolism provide evidence for additional factors beyond CYP2D6-inferred phenotype that may contribute to observed metabolite patterns [Abstract]. American Association for Clinical Chemistry.
  151. Biltaji E, Biskupiak J, Sherwin CMT, McMillin G, Brixner D (). Optimizing the value of pharmacogenetics risk screening among patients with polypharmacy: a healthcare system experience [Abstract]. Academy of Managed Care Pharmacy.

Other

  1. McMillin GA, Colby JM, Wabuyele SL (). Drug Exposure in Newborns. Clinical and Forensic Toxicology News (pp. 1-5).
  2. Hyun G, Li J, Bass AR, Mohapatra A, Woller SC, Lin H, Eby C, McMillin GA, Gage BF (2016 Nov). Erratum to: Use of signals and systems engineering to improve the safety of warfarin initiation. J Thromb Thrombolysis (42(4), p. 534). Netherlands.
  3. Signorelli H, Johnson-Davis K, McMillin G (). Nicotine Metabolite Testing. The IATDMCT Compass News and Views on TDM and CT from around the world (14(2), pp. 8-10).
  4. Wood KE, Krasowski MD, McMillin GA (). Drug Tests in Multiple Births. Clinical & Forensic Toxicology News (pp. 6-9).
  5. McMillin GA (). Pharmacogenetics could guide warfarin dosing. Clinical & Forensic Toxicology News ((June), pp. 1-10).
  6. McMillin G, Lyon E (July 2006 Invited Review). Contributions of genetic testing in personalized pharmacotherapy. Advance News Magazine for Administrators of the Laboratory (15(4), p. 20).

Video